AlphaGrep UK Ltd increased its holdings in Globus Medical, Inc. (NYSE:GMED – Free Report) by 345.1% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 19,587 shares of the medical device company’s stock after purchasing an additional 15,186 shares during the period. Globus Medical accounts for 0.4% of AlphaGrep UK Ltd’s holdings, making the stock its 10th biggest holding. AlphaGrep UK Ltd’s holdings in Globus Medical were worth $1,467,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Washington Trust Advisors Inc. grew its position in shares of Globus Medical by 116.8% during the second quarter. Washington Trust Advisors Inc. now owns 45,006 shares of the medical device company’s stock valued at $3,556,000 after purchasing an additional 24,250 shares in the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in Globus Medical in the 2nd quarter worth approximately $1,858,000. Illinois Municipal Retirement Fund raised its holdings in shares of Globus Medical by 24.5% during the 3rd quarter. Illinois Municipal Retirement Fund now owns 73,173 shares of the medical device company’s stock worth $5,481,000 after acquiring an additional 14,412 shares in the last quarter. Public Employees Retirement System of Ohio bought a new position in shares of Globus Medical during the 2nd quarter valued at approximately $7,941,000. Finally, Congress Asset Management Co. grew its holdings in shares of Globus Medical by 6.6% in the third quarter. Congress Asset Management Co. now owns 361,026 shares of the medical device company’s stock valued at $27,041,000 after purchasing an additional 22,401 shares in the last quarter. Institutional investors own 95.16% of the company’s stock.
Globus Medical Price Performance
Shares of Globus Medical stock opened at $66.79 on Friday. The stock has a market cap of $8.85 billion, a price-to-earnings ratio of 16.41, a PEG ratio of 1.04 and a beta of 0.98. Globus Medical, Inc. has a 1 year low of $66.63 and a 1 year high of $101.40. The firm’s 50-day moving average is $75.98 and its two-hundred day moving average is $82.19.
Insider Buying and Selling at Globus Medical
In other news, Director James Tobin sold 41,666 shares of the business’s stock in a transaction dated Tuesday, November 10th. The stock was sold at an average price of $75.16, for a total transaction of $3,131,616.56. Following the sale, the director owned 15,000 shares in the company, valued at approximately $1,127,400. The trade was a 73.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Ann D. Rhoads sold 5,000 shares of the company’s stock in a transaction dated Wednesday, November 4th. The shares were sold at an average price of $85.00, for a total transaction of $425,000.00. Following the transaction, the director owned 35,384 shares in the company, valued at approximately $3,007,640. This trade represents a 12.38% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 76,666 shares of company stock worth $5,794,017 over the last ninety days. Corporate insiders own 18.38% of the company’s stock.
Analysts Set New Price Targets
GMED has been the topic of several recent research reports. Wells Fargo & Company upped their target price on shares of Globus Medical from $99.00 to $100.00 and gave the company an “overweight” rating in a research report on Friday, November 6th. BTIG Research reissued a “neutral” rating on shares of Globus Medical in a research note on Friday, November 6th. UBS Group assumed coverage on shares of Globus Medical in a report on Tuesday, July 28th. They issued a “neutral” rating and a $82.00 target price for the company. Needham & Company LLC dropped their price target on shares of Globus Medical from $117.00 to $100.00 and set a “buy” rating for the company in a research note on Friday, November 6th. Finally, Truist Financial reduced their price objective on shares of Globus Medical from $100.00 to $90.00 and set a “buy” rating on the stock in a research report on Monday, November 9th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and seven have assigned a Hold rating to the stock. According to data from MarketBeat.com, Globus Medical has a consensus rating of “Moderate Buy” and a consensus target price of $96.08.
Get Our Latest Research Report on Globus Medical
Globus Medical Profile
Globus Medical is a medical device company focused on musculoskeletal care. Its products include implants and instruments used in spine surgery, as well as solutions for orthopedic trauma and other orthopedic procedures. The company also develops surgical technologies, including robotic navigation and imaging systems designed to support planning and guidance during procedures. Its portfolio expanded significantly in 2023 when Globus Medical completed its combination with NuVasive, a provider of spine care products and technologies.
Recommended Stories
- Five stocks we like better than Globus Medical
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Want to see what other hedge funds are holding GMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Globus Medical, Inc. (NYSE:GMED – Free Report).
Receive News & Ratings for Globus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Globus Medical and related companies with MarketBeat.com's FREE daily email newsletter.
